Private SLT laser glaucoma treatment cost UK 2026

What is selective laser trabeculoplasty (SLT)?

Selective laser trabeculoplasty (SLT) is an in-clinic laser procedure that lowers intra-ocular pressure (IOP) by improving the natural drainage of aqueous humour through the trabecular meshwork at the angle of the eye. SLT uses a frequency-doubled Q-switched Nd:YAG laser at 532 nanometres delivering very short (3 nanosecond) low-energy pulses that selectively target pigmented trabecular meshwork cells without causing collateral thermal damage. This selective action triggers a beneficial biological remodelling of the trabecular meshwork and macrophage clearance of debris, restoring outflow.

Unlike its older predecessor argon laser trabeculoplasty (ALT), SLT does not cause coagulative scarring of the meshwork; this is why it can be repeated safely and why it is the modern technique of choice. The Q-switched Nd:YAG SLT laser was first described by Latina and Park in 1995 and is now available on a wide range of platforms in UK clinics (Lumenis Selecta II, Ellex Tango, Ellex Solo, Quantel Optimis Fusion, Nidek YC-200, BVI Vitra Tango Reflex).

The procedure takes 5 to 10 minutes per eye, is done under topical anaesthetic at the slit-lamp with a gonioscopy lens, and is essentially painless apart from a small click sensation with each laser shot. Standard treatment is 360-degree SLT (the full circumference of the angle, typically 100 spots at 0.4 to 1.4 mJ), which is what the LiGHT trial used and is what NICE NG81 recommends.

UK 2026 SLT pricing, in detail

UK 2026 SLT pricing varies with whether the procedure is unilateral or bilateral, whether it is a first-time procedure or a repeat, and whether full diagnostic glaucoma work-up (OCT, fields, gonioscopy) is included in the package. The fee should be quoted as an all-inclusive package covering the consultant glaucoma assessment, the diagnostic tests, the laser itself and the structured 4 to 12 week follow-up.

For related glaucoma pricing see our private glaucoma surgery price guide, our iStent MIGS guide and our drops vs SLT vs MIGS overview.

What should be included in a private SLT package in the UK in 2026?

• Glaucoma-subspecialty consultant — a UK GMC specialist registered consultant ophthalmologist with documented glaucoma subspecialty fellowship, doing at least 100 SLT procedures a year, with audit data available on request.
• Full diagnostic work-up — Goldmann applanation tonometry, central corneal pachymetry, slit-lamp examination, dilated optic disc assessment, OCT of the optic nerve head (RNFL, GCL/IPL) and macula, Humphrey visual fields (24-2 standard, 10-2 if central / paracentral defects suspected), and Goldmann or Posner gonioscopy to confirm the angle is open and suitable for SLT.
• Indication confirmation — primary open-angle glaucoma (POAG), ocular hypertension (OHT meeting NICE NG81 treatment thresholds), pseudoexfoliation glaucoma, pigmentary glaucoma, or normal-tension glaucoma in selected cases.
• Pre-procedure planning — written explanation of the expected IOP-lowering effect (20 to 30 per cent at 12 months in responders), the response rate (75 to 85 per cent), the typical onset of effect (4 to 6 weeks), the duration of effect (a median of around 4 years in LiGHT) and the option to repeat SLT.
• 360-degree SLT — full circumference treatment as in the LiGHT trial protocol (approximately 100 spots, 0.4 to 1.4 mJ, titrated to small champagne-bubble end-point).
• Topical anaesthetic and gonioscopy contact lens — procedure delivered at the slit-lamp; you can drive home.
• Single-dose post-procedure anti-inflammatory cover — topical NSAID (e.g. ketorolac) or weak topical steroid for 3 to 5 days; some clinics give a single peri-procedure dose without any take-home drops.
• Structured 4 to 12 week follow-up — 1-day post-laser IOP check, 4-week IOP check, 12-week consultant review with repeat OCT or fields as indicated.
• CQC-registered premises with the latest report rated Good or Outstanding, transparent written pricing, and direct telephone access to the consultant for 90 days post-laser.
• Honest expectation-setting — about the 15 to 25 per cent non-response rate, the realistic 1 to 5 per cent of patients with a clinically meaningful IOP spike in the first 24 hours, and the lifelong need for glaucoma monitoring.

What does the evidence say about SLT?

SLT is one of the most rigorously evidence-supported interventions in modern ophthalmology, and the evidence base is consistent across the major datasets:

• LiGHT trial 3-year data (Gazzard et al., Lancet 2019) — landmark NIHR-funded UK randomised controlled trial of 718 patients with newly diagnosed POAG / OHT, comparing primary SLT against primary eye drops. SLT achieved target IOP at 3 years in 74.2 per cent of eyes without any drops, with similar disease stability, lower NHS lifetime cost, fewer cataract surgeries and lower trabeculectomy rate than the drops arm.
• LiGHT trial 6-year extension (Gazzard et al., Ophthalmology 2023) — sustained advantage of primary SLT at 6 years: 69.8 per cent of SLT eyes remained drop-free; fewer trabeculectomies (0 vs 13); lower rate of disease progression on visual fields; sustained better disease control. SLT was confirmed as cost-effective from the NHS perspective.
• NICE NG81 Glaucoma: Diagnosis and Management (2022 update) — on the back of LiGHT, NICE now recommends primary 360-degree SLT as first-line for newly diagnosed POAG and OHT requiring treatment, in preference to starting with daily eye drops. This was a major shift in UK glaucoma practice.
• European Glaucoma Society Guidelines (5th edition, 2025) — same recommendation; SLT positioned as a first-line option alongside selected prostaglandin drops, with patient preference and lifestyle informing the choice.
• AAO Primary Open-Angle Glaucoma Preferred Practice Pattern — SLT supported as an effective IOP-lowering procedure with good safety, used either as primary therapy or as an adjunct to drops; explicitly safe to repeat.
• Pseudoexfoliation and pigmentary glaucoma data — SLT tends to be particularly effective in pigmented angles, with even better IOP-lowering than in standard POAG in some series.
• Cost-effectiveness — SLT is cost-saving versus lifetime drops from the NHS perspective in the LiGHT trial; this drives current UK first-line recommendations.

In short: SLT works in about 75 to 85 per cent of eyes, lowers IOP by 20 to 30 per cent at 12 months, holds its effect for a median of around 4 years, can be safely repeated, avoids the cumulative ocular surface toxicity of drops, and is now the NICE first-line treatment for POAG and OHT.

SLT vs drops: which should I choose?

Both work by lowering intra-ocular pressure but they do so very differently:

• SLT (selective laser trabeculoplasty) — a single in-clinic 5 to 10 minute laser procedure under topical anaesthetic. Targets the trabecular meshwork to increase aqueous outflow. Effect typically lasts a median of around 4 years. Can be repeated. Avoids the daily-drop adherence problem, the ocular surface toxicity of preservatives (especially benzalkonium chloride), and the systemic side-effects of beta-blockers (bronchospasm, bradycardia) and prostaglandins (periorbital fat atrophy, iris darkening, eyelash growth). LiGHT trial: better long-term IOP control, fewer surgeries, lower NHS cost.
• Drops (prostaglandin analogues, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, Rho-kinase inhibitors) — lifelong daily eye drops with reasonable IOP-lowering efficacy when used adherently. Real-world adherence is around 50 to 70 per cent, falling further with multi-drop regimens. Cumulative ocular surface toxicity from preservatives and active ingredients is well-described, and can degrade quality of life and outcomes of any future glaucoma or cataract surgery.
• Combined SLT and drops — entirely reasonable when SLT alone does not achieve target IOP, or when there is established disease and rapid additional pressure-lowering is needed. The aim is the lowest number of drops necessary, especially preservative-free formulations.

The choice depends on the level of IOP-lowering needed, the stage of glaucoma damage, your tolerance for daily drops, your preferences and the clinical phenotype. NICE NG81 now positions SLT as the recommended first-line option for newly diagnosed POAG and OHT. A consultant glaucoma assessment is the only reliable way to decide.

Who is a good candidate for SLT?

The strongest case for SLT applies when one or more of the following are present:

• Newly diagnosed primary open-angle glaucoma (POAG) — SLT is the NICE-recommended first-line treatment in preference to starting with daily drops.
• Ocular hypertension (OHT) requiring treatment — per NICE NG81 thresholds (IOP > 24 mmHg with risk factors, or sooner if central corneal thickness, age, and family history place the patient at higher risk of conversion to glaucoma).
• Pseudoexfoliation glaucoma — SLT often gives an even better IOP-lowering response in pigmented angles than in standard POAG.
• Pigmentary glaucoma — particularly in younger myopic men where lifelong drops are problematic and where the pigmented trabecular meshwork responds well to SLT.
• Patients struggling with drops — ocular surface toxicity, allergy to preservatives, multi-drop regimens, poor adherence, dexterity / arthritis problems, dry eye disease, or contact lens wear.
• Patients planning cataract surgery — SLT can be done before, during or after cataract surgery and is a useful long-term pressure-lowering strategy.
• Normal-tension glaucoma (selected cases) — SLT has measurable IOP-lowering effect even at lower baseline pressures.

SLT is not usually advised in narrow / closed-angle glaucoma without a previous laser peripheral iridotomy or lens extraction, in inflammatory (uveitic) glaucoma during active inflammation, in neovascular glaucoma, in markedly dense pigment dispersion with already-low outflow, or in patients with very advanced glaucoma where a faster and more aggressive IOP reduction is required (where trabeculectomy, MIGS or tube surgery may be more appropriate). Suitability is always confirmed at consultation with gonioscopy.

NHS vs private SLT in the UK 2026

NHS access to SLT in the UK in 2026 is now broad. NICE NG81 (2022 update) recommends primary SLT as first-line for POAG and OHT, and most NHS glaucoma services across England, Wales, Scotland and Northern Ireland have rolled out direct-SLT or one-stop SLT clinics. Realistic NHS waits run between 8 and 26 weeks from referral to laser, depending on the trust and the urgency of the case. NHS care is excellent; the only practical limitation is timing.

Private SLT in the UK is the practical route when same-week treatment matters (for example, recent diagnosis with IOP in the 30s, or someone who is symptomatic and wants to avoid starting drops); when you want a specific glaucoma-subspecialty consultant; when you have private medical insurance that covers the procedure; or when you want a one-stop diagnostic-plus-laser visit on the same day. Most CQC-registered London glaucoma centres can complete the consultation, SLT and 12-week follow-up within a 6 to 14 week window.

Does private medical insurance cover SLT?

In 2026 the major UK private medical insurers (Bupa, AXA Health, Aviva, Vitality, WPA) generally cover SLT when there is a documented diagnosis of primary open-angle glaucoma, ocular hypertension meeting NICE NG81 treatment thresholds, pseudoexfoliation glaucoma, pigmentary glaucoma or another open-angle glaucoma diagnosis. The diagnostic glaucoma consultation, the SLT itself, the consultant fee and the post-procedure follow-up are usually covered subject to your policy excess and benefit limits.

Insurers usually do not cover SLT when there is no diagnosis of glaucoma or OHT, for screening alone in suspect cases without treatment threshold, or for routine drop-free conversion in well-controlled patients (where the indication is not strong). The clinical letter must clearly document the diagnosis, the IOP level, the OCT and visual field findings, the angle status on gonioscopy, and the rationale for SLT (NICE NG81 first-line recommendation, drop intolerance, drop adherence, ocular surface toxicity). Always pre-authorise in writing.

Risks and side-effects of SLT

SLT is one of the safest glaucoma interventions. The serious complication rate is very low. The realistic risks are mostly minor and transient, but they should be set out honestly:

• Transient IOP spike — in 1 to 5 per cent of patients in the first 1 to 24 hours; mitigated by a peri-procedure dose of apraclonidine or brimonidine; treated with short-term IOP-lowering drops or oral acetazolamide if needed.
• Mild anterior chamber inflammation — transient cell and flare for a few days, usually subclinical; covered by topical NSAID or weak topical steroid for 3 to 5 days.
• Mild blurred vision — for 30 to 60 minutes after the procedure from the topical anaesthetic and gonioscopy gel; resolves spontaneously.
• Mild headache or brow ache — for several hours; paracetamol is usually enough.
• Mild photophobia and redness — for 24 to 48 hours.
• Non-response — 15 to 25 per cent of eyes do not achieve a clinically meaningful IOP fall; drops or an alternative intervention are then considered.
• Loss of effect over time — SLT effect typically wanes over a median of around 4 years; can be repeated.
• Peripheral anterior synechiae — rare; more likely in narrow angles where SLT was inappropriate; avoided by gonioscopy first.
• Macular oedema — very rare; reported but plausibly coincidental in most cases; consider in patients with pre-existing macular disease.
• Hyphaema — very rare with SLT (versus more common with selective laser settings used in some legacy ALT protocols).
• Endothelial decompensation — theoretical; not a clinically meaningful issue in modern SLT.

The overall safety record of SLT is excellent; the LiGHT trial reported a serious adverse event rate not significantly different from the drops arm, and substantially lower trabeculectomy rates over 6 years.

What to expect after SLT

• Immediately after the procedure — mild blurred vision and a foreign-body sensation for 30 to 60 minutes from the topical anaesthetic and gonioscopy gel; you can usually drive home, although it is more comfortable to have a driver.
• Same day — topical NSAID or weak steroid for 3 to 5 days; you can resume normal activities, screen use and work the same day.
• 1-day IOP check — brief slit-lamp visit to confirm there is no IOP spike.
• 4-week IOP check — at this point most of the IOP-lowering effect is established.
• 12-week consultant review — repeat OCT and / or visual fields as indicated; consultant decides whether SLT alone has achieved target IOP or whether adjunctive drops are needed.
• Annual monitoring — lifelong annual review with IOP, OCT and visual fields to detect disease progression and to time repeat SLT or other interventions.
• Repeat SLT — if effect wanes after 18 to 36 months and target IOP is not maintained, repeat SLT can be safely offered (same fee).

How to choose a UK SLT clinic in 2026

• Clinical leadership — a UK GMC specialist registered consultant ophthalmologist with documented glaucoma subspecialty fellowship, doing at least 100 SLT procedures a year, with audit data available on request.
• Full diagnostic work-up — Goldmann tonometry, pachymetry, OCT optic nerve and macula, Humphrey visual fields, gonioscopy — all included in the package, not charged as add-ons.
• 360-degree SLT protocol — full circumference treatment as per the LiGHT trial, not partial 180-degree SLT, which has lower efficacy and is no longer the standard.
• Modern SLT platform — Lumenis Selecta II, Ellex Tango / Tango Reflex / Solo, Quantel Optimis Fusion, Nidek YC-200 or equivalent.
• Honest evidence-based consent — written information about the 75 to 85 per cent response rate, the median ~4-year duration of effect, the option to repeat, and the small risk of an early IOP spike.
• Transparent itemised pricing — the invoice should split consultation, OCT, visual fields, gonioscopy, SLT and post-procedure reviews so you can claim the appropriate components on insurance.
• CQC-registered premises with the latest report rated Good or Outstanding.
• Same consultant throughout — consultation, laser and 3-month follow-up done by the same glaucoma-subspecialty consultant.
• Annual monitoring on offer — the clinic should offer a structured annual glaucoma monitoring package.
• Direct access — a published 24/7 number for postoperative concerns and a same-day clinic slot if anything changes in the first 90 days.

Frequently asked questions

How much does private SLT laser glaucoma treatment cost in the UK in 2026?

UK 2026 self-pay SLT costs 850 to 1,800 pounds per eye and 1,400 to 2,800 pounds for bilateral SLT (both eyes in the same session), all-inclusive at CQC-registered glaucoma centres. The fee covers the consultant glaucoma assessment, OCT optic nerve and macula, gonioscopy, Humphrey visual fields where indicated, the 360-degree SLT procedure under topical anaesthetic, and the structured 4 to 12 week follow-up. Repeat SLT 18 to 36 months later (if effect wanes) is charged at the same fee. A direct-SLT same-day diagnostic-plus-laser package is 1,200 to 2,200 pounds in many UK centres.

Is SLT really better than starting with eye drops?

The LiGHT trial (Gazzard et al., Lancet 2019; 6-year update Ophthalmology 2023) randomised 718 UK patients with newly diagnosed POAG and OHT to primary SLT versus primary drops. SLT achieved better long-term IOP control, kept 69.8 per cent of eyes drop-free at 6 years, resulted in fewer trabeculectomies (0 vs 13), lower rates of disease progression on visual fields, similar quality-of-life, and was cost-saving from the NHS perspective. On the back of this, NICE NG81 (2022 update) recommends primary 360-degree SLT as first-line treatment in preference to starting with daily drops.

How much will SLT lower my eye pressure?

Typical IOP reduction is 20 to 30 per cent at 12 months in responders. The response rate is 75 to 85 per cent: most patients will get a meaningful drop in IOP from SLT alone. Pseudoexfoliation and pigmentary glaucoma often respond particularly well. About 15 to 25 per cent of eyes do not get a clinically meaningful IOP fall from SLT, in which case drops or another intervention are considered.

Does SLT hurt and how long does it take?

SLT is essentially painless. It takes 5 to 10 minutes per eye in clinic under topical anaesthetic at the slit-lamp with a gonioscopy lens. You feel a small click sensation with each laser shot but no real discomfort. Vision is mildly blurred for 30 to 60 minutes from the topical anaesthetic and gonioscopy gel. There is no incision, no needle and no general anaesthetic.

How long does SLT last and can it be repeated?

The IOP-lowering effect of SLT typically lasts a median of around 4 years in the LiGHT trial. SLT can be safely repeated, and repeat SLT has a similar response rate to the first treatment in most series. Some patients will need repeat SLT every 2 to 5 years; others get a much longer durable response. Repeat SLT is charged at the same fee as primary SLT.

Will the NHS pay for my SLT?

Yes. NICE NG81 (2022 update) recommends primary 360-degree SLT as first-line treatment for newly diagnosed POAG and OHT, in preference to starting with daily drops. NHS glaucoma services across the UK now offer direct-SLT or one-stop SLT clinics. Realistic NHS waits run between 8 and 26 weeks from referral to laser depending on the trust. NHS care is excellent and the only practical limitation is timing.

Will my private medical insurance cover SLT?

In 2026 Bupa, AXA, Aviva, Vitality and WPA generally cover SLT when there is a documented diagnosis of primary open-angle glaucoma, ocular hypertension meeting NICE NG81 treatment thresholds, pseudoexfoliation glaucoma or pigmentary glaucoma. The clinical letter must document the diagnosis, the IOP level, the OCT and visual field findings, the angle status on gonioscopy and the rationale for SLT. Always pre-authorise in writing.

Could SLT replace all of my drops?

Often, yes. In the LiGHT trial 69.8 per cent of SLT-first eyes were still drop-free at 6 years with good disease control. The chance of becoming drop-free is highest when SLT is offered early (newly diagnosed POAG or OHT) and the baseline IOP is not extremely high. In established more advanced disease or very high baseline IOPs, SLT often reduces but does not eliminate the need for drops. The realistic plan is discussed at consultation.

What are the risks of SLT?

SLT is one of the safest glaucoma interventions. The realistic risks are a small early IOP spike in 1 to 5 per cent (mitigated by peri-procedure apraclonidine and managed with short-term drops if needed), transient mild anterior chamber inflammation (covered by topical NSAID or weak steroid for 3 to 5 days), transient blurred vision and brow ache for a few hours, and non-response in 15 to 25 per cent. Serious complications (macular oedema, hyphaema, peripheral anterior synechiae) are very rare. The LiGHT trial showed a serious adverse event rate similar to drops and lower trabeculectomy rates over 6 years.

When can I drive after SLT?

Most patients drive home the same afternoon. Vision is mildly blurred for 30 to 60 minutes from the topical anaesthetic and gonioscopy gel; many patients prefer to have someone drive them home for that short window, but no formal DVLA restriction applies to SLT itself. Driving is fine the day after the procedure assuming the better eye meets the DVLA standard.

Can I have SLT if I have already had cataract surgery?

Yes. SLT can be performed before, during or after cataract surgery and remains effective in pseudophakic eyes. Many glaucoma patients have cataract surgery first, and then SLT (or repeat SLT) is offered to keep IOP controlled. Some surgeons combine cataract surgery with iStent MIGS or other angle-based MIGS as an alternative pathway in patients with concurrent visually significant cataract and glaucoma.

SLT versus iStent or other MIGS — which is right for me?

SLT is the first-line laser intervention for POAG and OHT in patients who do not have a visually significant cataract. iStent inject W and other MIGS devices (Hydrus, PreserFlo, XEN) are implanted at the time of cataract surgery in patients who have both cataract and glaucoma. SLT is non-invasive, in-clinic, repeatable and cheaper; MIGS is more invasive but is a single combined-with-cataract intervention. Both have their place in modern glaucoma practice. See our iStent MIGS guide and our drops vs SLT vs MIGS overview.

Methodology and sources

This UK 2026 patient pricing and pathway guide was prepared by the Eye Surgery Clinic editorial team and reviewed by a UK GMC-registered consultant ophthalmologist with glaucoma subspecialty interest. Pricing reflects a CQC-registered UK glaucoma sample audited against published 2024 to 2026 self-pay tariffs from the major UK glaucoma providers. Clinical statements are anchored on:

• Gazzard G, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT). Lancet 2019; 393(10180): 1505-1516
• Gazzard G, et al. Six-year outcomes of the LiGHT trial. Ophthalmology 2023 (LiGHT 6-year extension)
• NICE NG81 Glaucoma: Diagnosis and Management (2022 update)
• European Glaucoma Society Guidelines, 5th edition (2025)
• Royal College of Ophthalmologists Glaucoma Commissioning Guidance
• AAO Primary Open-Angle Glaucoma Preferred Practice Pattern
• UK and Eire Glaucoma Society (UKEGS) statements on SLT
• Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res 1995; 60: 359-371 (foundational SLT paper)
• Care Quality Commission (CQC) inspection reports for major UK glaucoma units
• General Medical Council (GMC) Good Medical Practice and consent guidance

This page is editorial and educational. It is not personalised medical advice. SLT suitability can only be confirmed by an in-person consultant glaucoma consultation with a full work-up.

Book your UK SLT consultation

Speak directly to a UK GMC-registered consultant ophthalmologist with glaucoma subspecialty interest. Same-week consultation slots are usually available. OCT optic nerve and macula, Humphrey visual fields, gonioscopy and Goldmann tonometry included. Confidential, no-obligation review of whether SLT, drops, MIGS or trabeculectomy is right for you.

Related reading: Private glaucoma surgery cost UK · Private iStent MIGS surgery London · Drops vs SLT vs MIGS overview · Private cataract surgery prices